AKTS
AKTS
NASDAQ · Biotechnology

Aktis Oncology Inc

$30.11
+0.67 (+2.28%)
Financial Highlights (FY 2026)
Revenue
6.62M
Net Income
-64,965,645
Gross Margin
-11.5%
Profit Margin
-980.9%
Rev Growth
+147.5%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin -11.5% -2.5% 56.2% 56.2%
Operating Margin -1,149.5% -550.1% -11.0% -9.1%
Profit Margin -980.9% -582.6% -8.6% -10.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 6.62M 9.1K 117.17M 104.10M
Gross Profit -761,058 -229 65.90M 58.55M
Operating Income -76,145,227 -50,184 -12,934,350 -9,474,280
Net Income -64,965,645 -50,362 -10,038,830 -10,712,566
Gross Margin -11.5% -2.5% 56.2% 56.2%
Operating Margin -1,149.5% -550.1% -11.0% -9.1%
Profit Margin -980.9% -582.6% -8.6% -10.3%
Rev Growth +147.5% +60.5% +1.7% -5.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 152.8K 57.51M 59.72M
Total Equity 299.4K 766.73M 731.61M
D/E Ratio 0.51 0.08 0.08
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -73,753,019 -48,936 -16,056,956 -12,934,270
Free Cash Flow -11,744,338 -10,882,988